Summary & Overview
HCPCS Level II J1597: Glycopyrrolate Injection, 0.1 mg
HCPCS Level II code J1597 designates a 0.1 mg injectable unit of glycopyrrolate. Glycopyrrolate is an anticholinergic agent used in multiple clinical contexts, including control of secretions, preoperative medication, and management of certain autonomic disorders. As a drug-specific HCPCS Level II code, J1597 is used on medical claims to report the administered dose of glycopyrrolate when billed separately from procedural services. Clear identification and use of this code matter nationally for accurate drug utilization tracking, reimbursement, and clinical documentation.
Key payers addressed in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the code’s clinical context and billing purpose, payer coverage considerations, typical sites of service, and commonly used claim modifiers (listed separately). The publication summarizes benchmark elements such as typical use cases and claim reporting conventions, notes where input data were unavailable, and highlights policy or billing considerations relevant to national stakeholders. This material provides clinicians, billing professionals, and policy analysts with a focused reference for coding and documentation of glycopyrrolate injections using HCPCS Level II code J1597.
Billing Code Overview
HCPCS Level II code J1597 represents an injectable formulation of glycopyrrolate, specified as Injection, glycopyrrolate (glyrx-pf), 0.1 mg. This code denotes administration of a 0.1 mg unit of glycopyrrolate for therapeutic use.
Service Type: Drug administration / Injectable medication
Typical Site of Service: Outpatient clinics, hospital outpatient departments, physician office settings, and infusion centers
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with chronic drooling or sialorrhea due to neurological conditions such as Parkinson disease, cerebral palsy, or amyotrophic lateral sclerosis who requires pharmacologic reduction of secretions. The patient presents to an outpatient infusion clinic, hospital inpatient unit, or skilled nursing facility for administration of J1597 (injection, glycopyrrolate, 0.1 mg). The clinical workflow includes verification of indication and weight, medication reconciliation, informed consent for off-label or indicated use, baseline vital signs and anticholinergic risk assessment, preparation of the correct dose (calculated from the supplied concentration per 0.1 mg units), and administration via intramuscular or intravenous injection per institutional protocol. Post-administration monitoring for anticholinergic adverse effects (tachycardia, urinary retention, dry mouth, confusion) is performed for an appropriate observation interval. Documentation includes indication, dose administered (units of J1597), route, site, lot number, and any immediate reactions. Billing uses HCPCS J1597 with appropriate modifiers to reflect circumstances such as distinct procedural services, bilateral procedures, or drug wastage as applicable.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
JW |